About: Weight gain associated with atypical and typical antipsychotics during treatment of adolescent schizophrenic psychoses: A retrospective study

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Weight gain associated with atypical and typical antipsychotics during treatment of adolescent schizophrenic psychoses: A retrospective study Goto Sponge NotDistinct Permalink

An Entity of Type : http://linked.opendata.cz/ontology/domain/vavai/Vysledek, within Data Space : linked.opendata.cz associated with source document(s)

Attributes	Values
rdf:type	skos:Concept http://linked.opendata.cz/ontology/domain/vavai/Vysledek
Description	The aim was to assess weight changes associated with atypical (AAP) and typical (TAP) antipsychotics in patients with early-onset schizophrenia and related psychoses. Retrospective study included 109 patients (52 b, 57 g) with a mean age of 15.8 years. The patients were evaluated based to their medical records prior to therapy, then after 1, 3, and 6 weeks of treatment. During the first week of treatment, the AAP group (n = 85) gained 1.5% of baseline weight whereas the TAP group (n = 24) gained only 0.2%. Expressed as absolute values, patients in our sample gained an average of 3.4 kg on AAP and 2.0 kg on TAP during 6 weeks of treatment (n.s.). The patients gained, on average, 3.6 kg on risperidone, 4.4 kg on olanzapine, and 2.1 kg on clozapine during the six weeks of treatment (n.s.). We did not find a difference in weight gain between the AAP and TAP groups, as large as has been described in the literature. The aim was to assess weight changes associated with atypical (AAP) and typical (TAP) antipsychotics in patients with early-onset schizophrenia and related psychoses. Retrospective study included 109 patients (52 b, 57 g) with a mean age of 15.8 years. The patients were evaluated based to their medical records prior to therapy, then after 1, 3, and 6 weeks of treatment. During the first week of treatment, the AAP group (n = 85) gained 1.5% of baseline weight whereas the TAP group (n = 24) gained only 0.2%. Expressed as absolute values, patients in our sample gained an average of 3.4 kg on AAP and 2.0 kg on TAP during 6 weeks of treatment (n.s.). The patients gained, on average, 3.6 kg on risperidone, 4.4 kg on olanzapine, and 2.1 kg on clozapine during the six weeks of treatment (n.s.). We did not find a difference in weight gain between the AAP and TAP groups, as large as has been described in the literature. (en)
Title	Weight gain associated with atypical and typical antipsychotics during treatment of adolescent schizophrenic psychoses: A retrospective study Weight gain associated with atypical and typical antipsychotics during treatment of adolescent schizophrenic psychoses: A retrospective study (en)
skos:prefLabel	Weight gain associated with atypical and typical antipsychotics during treatment of adolescent schizophrenic psychoses: A retrospective study Weight gain associated with atypical and typical antipsychotics during treatment of adolescent schizophrenic psychoses: A retrospective study (en)
skos:notation	RIV/68081740:_____/09:00333993!RIV10-AV0-68081740
http://linked.open...avai/riv/aktivita	Z
http://linked.open...avai/riv/aktivity	Z(AV0Z70250504), Z(MSM0021620849)
http://linked.open...iv/cisloPeriodika	2
http://linked.open...vai/riv/dodaniDat	2010
http://linked.open...aciTvurceVysledku	Blatný, Marek Urbánek, Tomáš
http://linked.open.../riv/druhVysledku	J - Článek v odborném periodiku
http://linked.open...iv/duvernostUdaju	S - Úplné a pravdivé údaje nepodléhající ochraně podle zvláštních právních předpisů
http://linked.open...titaPredkladatele	Psychologický ústav AV ČR, v. v. i.
http://linked.open...dnocenehoVysledku	351832
http://linked.open...ai/riv/idVysledku	RIV/68081740:_____/09:00333993
http://linked.open...riv/jazykVysledku	eng - angličtina
http://linked.open.../riv/klicovaSlova	schizophrenia; antipsychotics; weight gain (en)
http://linked.open.../riv/klicoveSlovo	schizophrenia antipsychotics weight gain
http://linked.open...odStatuVydavatele	SE - Švédské království
http://linked.open...ontrolniKodProRIV	[CE18A3ACCDAB]
http://linked.open...i/riv/nazevZdroje	Neuroendocrinology Letters
http://linked.open...in/vavai/riv/obor	AN
http://linked.open...ichTvurcuVysledku	2 (xsd:int)
http://linked.open...cetTvurcuVysledku	4 (xsd:int)
http://linked.open...UplatneniVysledku	2009
http://linked.open...v/svazekPeriodika	30
http://linked.open...iv/tvurceVysledku	Blatný, Marek Urbánek, Tomáš Hrdlička, M. Zedková, I.
http://linked.open...ain/vavai/riv/wos	000269663900013
http://linked.open...n/vavai/riv/zamer	Člověk v kontextech celoživotního vývoje Neuropsychiatrické aspekty neurodegenerativních onemocnění
issn	0172-780X
number of pages	6 (xsd:int)
is http://linked.open...avai/riv/vysledek of	Weight gain associated with atypical and typical antipsychotics during treatment of adolescent schizophrenic psychoses: A retrospective study Weight gain associated with atypical and typical antipsychotics during treatment of adolescent schizophrenic psychoses: A retrospective study Weight gain associated with atypical and typical antipsychotics during treatment of adolescent schizophrenic psychoses: A retrospective study Weight gain associated with atypical and typical antipsychotics during treatment of adolescent schizophrenic psychoses: A retrospective study

Faceted Search & Find service v1.16.118 as of Jun 21 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3240 as of Jun 21 2024, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (126 GB total memory, 19 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software